Ibaraki, Japan

Makoto Ogo


 

Average Co-Inventor Count = 13.9

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2005-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Makoto Ogo

Introduction

Makoto Ogo is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds with potential therapeutic applications. With a total of two patents to his name, Ogo's work focuses on compounds that exhibit excellent AMPA receptor inhibitory action and kainate inhibitory action.

Latest Patents

Ogo's latest patents include innovative 1,2-dihydropyridine compounds and their manufacturing methods. These compounds are represented by specific chemical formulas, where Q can indicate NH, O, or S. The R groups in the formula can vary, representing hydrogen atoms, halogen atoms, or alkyl groups. The compounds are designed to provide significant inhibitory action on AMPA and kainate receptors, which are crucial in various neurological processes.

Career Highlights

Throughout his career, Makoto Ogo has worked with prominent companies in the pharmaceutical industry, including Eisai Company, Limited and Eisai R&D Management Co., Ltd. His experience in these organizations has allowed him to contribute to important research and development projects, enhancing the understanding of receptor interactions and potential drug applications.

Collaborations

Ogo has collaborated with esteemed colleagues such as Satoshi Nagato and Kohshi Ueno. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of medicinal chemistry.

Conclusion

Makoto Ogo's contributions to the field of chemistry through his patents and collaborations highlight his role as an influential inventor. His work on 1,2-dihydropyridine compounds showcases the potential for new therapeutic agents in treating neurological conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…